Form 8-K - Current report:
SEC Accession No. 0001558370-25-011671
Filing Date
2025-08-19
Accepted
2025-08-19 16:15:16
Documents
16
Period of Report
2025-08-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pmn-20250813x8k.htm   iXBRL 8-K 38998
2 EX-1.1 pmn-20250813xex1d1.htm EX-1.1 261195
3 EX-5.1 pmn-20250813xex5d1.htm EX-5.1 15159
4 GRAPHIC pmn-20250813xex5d1001.jpg GRAPHIC 3086
  Complete submission text file 0001558370-25-011671.txt   502709

Data Files

Seq Description Document Type Size
5 EX-101.SCH pmn-20250813.xsd EX-101.SCH 4155
6 EX-101.DEF pmn-20250813_def.xml EX-101.DEF 2871
7 EX-101.LAB pmn-20250813_lab.xml EX-101.LAB 17906
8 EX-101.PRE pmn-20250813_pre.xml EX-101.PRE 11837
18 EXTRACTED XBRL INSTANCE DOCUMENT pmn-20250813x8k_htm.xml XML 5044
Mailing Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2
Business Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2 416-847-6898
ProMIS Neurosciences Inc. (Filer) CIK: 0001374339 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41429 | Film No.: 251231955
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)